BACKGROUND: Monitoring of renal function becomes increasingly important in the aging population of HIV-1 infected patients. We compared Cockroft & Gault (C&G), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD), Cystatin C- and 24 h urine-based estimated GFR (eGFR) with the gold standard, measured GFR (mGFR) using [125I]-iothalamate. METHODS: Substudy within a randomized, multinational trial comparing continuing zidovudine/ lamivudine with switching to tenofovir/ emtricitabine in patients with suppressed HIV-1 infection. Accuracy (defined as the mean difference between eGFR and mGFR) and precision (defined as standard deviation (SD) of the mean difference between eGFR and mGFR) of the eGFRs were calculated using linear regression and Bland & Altman analysis. RESULTS: We included 19 patients, 18 men, 15 Caucasian, mean (SD) age 46.0 y (± 8.9) and BMI 23.9 kg/m2 (± 3.0). Mean (SD) mGFR was 102 ml/min/1.73 m2 (± 19), 4 patients had mild renal dysfunction. All eGFRs tended to underestimate true GFR, with best accuracy for C&G (-1 ml/min/1.73 m2), CKD-EPI (-1 ml/min/1.73 m2), 24 hcreatinine clearance (-2 ml/min/1.73 m2) and MDRD-6 (0 ml/min/1.73 m2), and worst for cystatin C-based (-9 ml/min/1.73 m2) and MDRD-4 estimations (-10 ml/min/1.73 m2). Accuracy worsened at higher mGFR, but was not significantly influenced by age. C&G tended to overestimate at higher BMI. Precision was comparable for all GFR estimations. CONCLUSIONS: In this limited number of patients with preserved renal function and suppressed HIV-infection C&G and CKD-EPI appeared to be the best reflection of real GFR and most practical tool for monitoring GFR.
RCT Entities:
BACKGROUND: Monitoring of renal function becomes increasingly important in the aging population of HIV-1 infectedpatients. We compared Cockroft & Gault (C&G), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD), Cystatin C- and 24 h urine-based estimated GFR (eGFR) with the gold standard, measured GFR (mGFR) using [125I]-iothalamate. METHODS: Substudy within a randomized, multinational trial comparing continuing zidovudine/ lamivudine with switching to tenofovir/ emtricitabine in patients with suppressed HIV-1 infection. Accuracy (defined as the mean difference between eGFR and mGFR) and precision (defined as standard deviation (SD) of the mean difference between eGFR and mGFR) of the eGFRs were calculated using linear regression and Bland & Altman analysis. RESULTS: We included 19 patients, 18 men, 15 Caucasian, mean (SD) age 46.0 y (± 8.9) and BMI 23.9 kg/m2 (± 3.0). Mean (SD) mGFR was 102 ml/min/1.73 m2 (± 19), 4 patients had mild renal dysfunction. All eGFRs tended to underestimate true GFR, with best accuracy for C&G (-1 ml/min/1.73 m2), CKD-EPI (-1 ml/min/1.73 m2), 24 hcreatinine clearance (-2 ml/min/1.73 m2) and MDRD-6 (0 ml/min/1.73 m2), and worst for cystatin C-based (-9 ml/min/1.73 m2) and MDRD-4 estimations (-10 ml/min/1.73 m2). Accuracy worsened at higher mGFR, but was not significantly influenced by age. C&G tended to overestimate at higher BMI. Precision was comparable for all GFR estimations. CONCLUSIONS: In this limited number of patients with preserved renal function and suppressed HIV-infection C&G and CKD-EPI appeared to be the best reflection of real GFR and most practical tool for monitoring GFR.
Authors: Christina M Wyatt; Douglas Kitch; Samir K Gupta; Camlin Tierney; Eric S Daar; Paul E Sax; Belinda Ha; Kathleen Melbourne; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Lene Ryom; Jens D Lundgren; Mike Ross; Ole Kirk; Matthew Law; Philippe Morlat; Eric Fontas; Colette Smit; Christoph A Fux; Camilla I Hatleberg; Stéphane de Wit; Caroline A Sabin; Amanda Mocroft Journal: J Infect Dis Date: 2016-08-02 Impact factor: 5.226
Authors: Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren Journal: J Infect Dis Date: 2013-02-04 Impact factor: 5.226
Authors: Lesley A Inker; Christina Wyatt; Rebecca Creamer; James Hellinger; Matthew Hotta; Maia Leppo; Andrew S Levey; Aghogho Okparavero; Hiba Graham; Karen Savage; Christopher H Schmid; Hocine Tighiouart; Fran Wallach; Zipporah Krishnasami Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Aghogho A Okparavero; Hocine Tighiouart; Zipporah Krishnasami; Christina M Wyatt; Hiba Graham; James Hellinger; Lesley A Inker Journal: Antivir Ther Date: 2013-08-20
Authors: Willemijn L Eppenga; Matthijs van Luin; Clemens Richter; Hieronymus J Derijks; Peter A G M De Smet; Michel Wensing Journal: J Nephrol Date: 2013-12-20 Impact factor: 3.902
Authors: Flávia Vanesca Felix Leão; Regina Célia de Menezes Succi; Daisy Maria Machado; Aída de Fátima Thomé Barbosa Gouvêa; Fabiana Bononi do Carmo; Suenia Vasconcelos Beltrão; Maria Aparecida de Paula Cançado; João Tomas de Abreu Carvalhaes Journal: Pediatr Nephrol Date: 2015-12-04 Impact factor: 3.714
Authors: Lene Ryom; Jens Dilling Lundgren; Peter Reiss; Ole Kirk; Matthew Law; Mike Ross; Phillip Morlat; Christoph Andreas Fux; Eric Fontas; Stephane De Wit; Antonella D'Arminio Monforte; Wafaa El-Sadr; Andrew Phillips; Camilla Ingrid Hatleberg; Caroline Sabin; Amanda Mocroft Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Willemijn L Eppenga; Cornelis Kramers; Hieronymus J Derijks; Michel Wensing; Jack F M Wetzels; Peter A G M De Smet Journal: PLoS One Date: 2015-03-05 Impact factor: 3.240